Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Preclinical results of a CD200-directed antibody in AML

Namrata Rastogi • 2 Apr 2019
BSH 2019
Acute Myeloid Leukemia Leukemia Antibodies TTI-CD200

CD200 is an important immune checkpoint protein, whose expression is associated with poor prognosis. Here, Namrata Rastogi, PhD, Cardiff University, Cardiff, UK, discusses the promising preclinical investigation of a CD200 blocking antibody in acute myeloid leukemia (AML) and exciting plans for a Phase I trial. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Namrata Rastogi

2:06
Defining the role of NFIC in AML
Namrata Rastogi • 2 Apr 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals